Citizens Maintains Market Outperform on Haemonetics, Raises Price Target to $144
Citizens analyst Daniel Stauder maintains Haemonetics (NYSE:HAE) with a Market Outperform and raises the price target from $115 to $144.
Last updated: 2026-11-19 07:45:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Haemonetics Corporation (HAE) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NYSE. The stock is currently priced at $122.82, with a market capitalization of $5.51B and a P/E ratio of 52.99. Over the past 52 weeks, its price has ranged from $51.00 to $132.00. This page covers its latest market performance, valuation, price trends and company information.
$5.51B | |
$120.78 | |
$126.63 | |
$119.81 | |
$120.92 | |
407.12K | |
666.58K | |
52.99 | |
$132.00 | |
$51.00 | |
-- | |
2026-09-26 |
Haemonetics Corporation (HAE) last closed at $122.82 as of 2026-11-19 00:31:00, up 1.60% ($1.94) from the previous close of $120.92.
During the latest regular trading session, HAE traded between $119.81 and $126.63, with a volume of 407.12K shares. The closing price was near the middle and near the upper end of its 52-week range.
Over the past seven days, Haemonetics Corporation (HAE) moved from $122.36 to $122.82, representing a gain of 0.38% ($0.46).
The stock traded between $116.68 and $126.63 during the period. The latest price is near the middle of the 7-day range, indicating range-bound.
The average daily volume was 561.88 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 88.7%
HAE is currently trading at $122.82, placing it 88.7% of the way from its 52-week low of $51.00 to its 52-week high of $132.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The Plasma segment includes end-to-end collection technologies, automated plasmapheresis systems (such as the NexSys PCS device), and donor management software designed for commercial plasma collectors. Hospital segment includes Blood Management Technologies (hemostasis analyzers, cell salvage systems) and Interventional Technologies. And the Blood Center provides solutions and devices enabling blood centers to harvest essential components like platelets and red blood cells.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 3,009 |
| Exchange | NYSE |
| Company Website |
Latest news related to Haemonetics Corporation and HAE stock.
Citizens analyst Daniel Stauder maintains Haemonetics (NYSE:HAE) with a Market Outperform and raises the price target from $115 to $144.
Analysts initiated coverage on UCTT, DNLI, HAE, MTRI and ADI, assigning ratings from Equal-Weight to Buy and targets of $33-$505.
Jefferies analyst Young Li initiates coverage on Haemonetics (NYSE:HAE) with a Buy rating and announces Price Target of $150.
Eligible investors can buy real shares of Haemonetics Corporation (HAE) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to HAE, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between HAE shares and USD.
HAE Shares to USD
1.00 HAE shares = 122.824 USD
Calculations are estimates based on the latest available price and are for reference only.